Breaking News

WuXi PharmaTech, Pharmacyclics Enter Supply Pact

November 15, 2013

WuXi's manufacturing facilities pass FDA inspection

WuXi PharmaTech's subsidiary, Shanghai SynTheAll (STA) Pharmaceutical Co., has entered into a supply agreement with Pharmacyclics, Inc. This follows a successful development and clinical manufacturing partnership for Pharmacyclics expedited NDA and FDA approval for Imbruvica for the treatment of patients with mantle cell lymphoma. The FDA conducted a GMP pre-approval inspection of WuXi's manufacturing facilities in August, with no Form 483 observations.
 
Imbruvica is an oral therapy that inhibits a protein called Bruton's tyrosine kinase (BTK), a key signaling molecule that plays an important role in the survival of malignant B cells. Imbruvica blocks signals that tell malignant B cells to grow and divide uncontrollably. Imbruvica has been granted three Breakthrough Therapy Designations by the FDA, a first for an oncology drug.  These designations are intended to expedite the development and review of drugs for serious or life-threatening conditions.  
 
"It is important that we work with a development partner with expertise in both clinical and commercial supply, as well as U.S. and worldwide GMP regulations, to ensure reliable quality supply to patients," said Heow Tan, chief of technical operations at Pharmacyclics. "STA's extensive experience will help us meet the demands of clinical and commercial supply for Imbruvica."
 
"We are very pleased and honored that Pharmacyclics has selected STA, WuXi's small-molecule development and manufacturing business unit, as a key partner for this supply," said Dr. Ge Li, chairman and chief executive officer of WuXi. "WuXi is determined to help our partners introduce innovative breakthrough drugs like Imbruvica to benefit patients around the world."

Related Contract Manufacturing:

Related Packaging:

Related Compliance:

  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks